You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSucralfate
Accession NumberDB00364  (APRD01238)
TypeSmall Molecule
GroupsApproved
Description

A basic aluminum complex of sulfated sucrose. [PubChem]

Structure
Thumb
Synonyms
Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
Sucralfat
Sucralfate
Sucralfato
Sucralfatum
External Identifiers
  • CGA-6J
  • OS 202
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carafatesuspension1 g/10mLoralPhysicians Total Care, Inc.1996-03-12Not applicableUs
Carafatetablet1 g/1oralAptalis Pharma US, Inc.1981-10-30Not applicableUs
Carafatesuspension1 g/10mLoralAptalis Pharma Inc.1993-12-16Not applicableUs
Dom-sucralfatetablet1000 mgoralDominion Pharmacal1999-09-15Not applicableCanada
Nu-sucralfate - Tab 1gmtablet1 goralNu Pharm Inc1994-12-312012-09-04Canada
PMS-sucralfatetablet1000 mgoralPharmascience Inc1999-02-23Not applicableCanada
Sucralfatesuspension1 g/10mLoralVista Pharm, Inc.2012-08-16Not applicableUs
Sucralfatesuspension1 g/10mLoralPharmaceutical Associates, Inc.2009-11-19Not applicableUs
Sucralfatetablet1 g/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sucralfatetablet1 g/1oralREMEDYREPACK INC.2011-07-21Not applicableUs
Sucralfatetablet1 g/1oralPd Rx Pharmaceuticals, Inc.1996-11-01Not applicableUs
Sucralfatetablet1 g/1oralREMEDYREPACK INC.2010-09-29Not applicableUs
Sucralfatesuspension1 g/10mLoralCardinal Health2009-11-19Not applicableUs
Sucralfatetablet1 g/1oralAphena Pharma Solutions Tennessee, Llc1996-11-01Not applicableUs
Sucralfatesuspension1 g/10mLoralCardinal Health2012-08-16Not applicableUs
Sucralfatesuspension1 g/10mLoralPrecision Dose Inc.2003-08-21Not applicableUs
Sucralfatetablet1 g/1oralActavis Pharma, Inc.1996-11-01Not applicableUs
Sucralfatesuspension1 g/10mLoralPhysicians Total Care, Inc.2005-05-24Not applicableUs
Sucralfate-1 - Tab 1gtablet1 goralPro Doc Limitee1995-12-31Not applicableCanada
Sulcratetablet1 goralAptalis Pharma Canada Inc1995-12-31Not applicableCanada
Sulcrate Sus 100mg/mlsuspension100 mgoralLabs Nordic Laboratories Inc. Subsidary Of M.M.D.C.1990-12-311996-09-09Canada
Sulcrate Suspension Plussuspension1 goralAptalis Pharma Canada Inc1995-12-31Not applicableCanada
Teva-sucralfatetablet1 goralTeva Canada Limited1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sucralfate - Tab 1gtablet1 goralApotex Inc1994-12-31Not applicableCanada
Sucralfatetablet1 g/1oralCardinal Health2011-05-27Not applicableUs
Sucralfatetablet1 g/1oralTeva Pharmaceuticals USA Inc1996-11-11Not applicableUs
Sucralfatetablet1 g/1oralGolden State Medical Supply, Inc.2009-07-01Not applicableUs
Sucralfatetablet1 g/1oralMedsource Pharmaceuticals1996-11-11Not applicableUs
Sucralfatetablet1 g/1oralCardinal Health2013-09-24Not applicableUs
Sucralfatetablet1 g/1oralAv Kare, Inc.2014-01-17Not applicableUs
Sucralfatetablet1 g/1oralUDL Laboratories, Inc.2011-05-272015-12-29Us
Sucralfatetablet1 g/1oralPhysicians Total Care, Inc.2005-05-23Not applicableUs
Sucralfatetablet1 g/1oralLevista, Inc.2009-07-012016-03-29Us
Sucralfatetablet1 g/1oralMc Kesson Contract Packaging2011-11-29Not applicableUs
Sucralfatetablet1 g/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sucralfatetablet1 g/1oralNostrum Laboratories, Inc.2009-07-01Not applicableUs
Sucralfatetablet1 g/1oralPreferred Pharmaceuticals Inc.2015-10-27Not applicableUs
Sucralfatetablet1 g/1oralNorthwind Pharmaceuticals, LLC2015-02-09Not applicableUs
Sucralfatetablet1 g/1oralSTAT Rx USA LLC2009-07-01Not applicableUs
Sucralfatetablet1 g/1oralAmerican Health Packaging2012-03-01Not applicableUs
Sucralfatetablet1 g/1oralMylan Institutional Inc.2013-09-24Not applicableUs
Sucralfatetablet1 g/1oralCardinal Health2010-01-082016-03-11Us
Sucralfatetablet1 g/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-08Not applicableUs
Sucralfatetablet1 g/1oralbryant ranch prepack2010-01-08Not applicableUs
Sucralfatetablet1 g/1oralLake Erie Medical DBA Quality Care Products LLC1996-11-11Not applicableUs
Sucralfatetablet1 g/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1996-11-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AntepsinOrion
SucramalMenarini
SucraxolMedifarma
UlcogantMerck
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIXX73205DH5
CAS number54182-58-0
WeightAverage: 1448.682
Monoisotopic: 1447.588619666
Chemical FormulaC11H28Al8O51S8
InChI KeyInChIKey=MNQYNQBOVCBZIQ-JQOFMKNESA-A
InChI
InChI=1S/C11H20O35S8.8Al.16H2O/c12-47(13,14)36-1-3-4(41-49(18,19)20)5(42-50(21,22)23)6(43-51(24,25)26)9(38-3)39-11(2-37-48(15,16)17)8(45-53(30,31)32)7(44-52(27,28)29)10(40-11)46-54(33,34)35;;;;;;;;;;;;;;;;;;;;;;;;/h3-10H,1-2H2,(H,12,13,14)(H,15,16,17)(H,18,19,20)(H,21,22,23)(H,24,25,26)(H,27,28,29)(H,30,31,32)(H,33,34,35);;;;;;;;;16*1H2/q;8*+3;;;;;;;;;;;;;;;;/p-24/t3-,4-,5+,6-,7+,8+,9+,10-,11-;;;;;;;;;;;;;;;;;;;;;;;;/m1......................../s1
IUPAC Name
[({[(2S,3R,4S,5R,6R)-4,5-bis({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-6-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]-2-{[(2R,3S,4S,5R)-3,4,5-tris({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)-2-[({[(dihydroxyalumanyl)oxy]sulfonyl}oxy)methyl]oxolan-2-yl]oxy}oxan-3-yl]oxy}sulfonyl)oxy]alumanediol
SMILES
O[Al](O)OS(=O)(=O)OC[[email protected]]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[[email protected]](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[[email protected]](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as disaccharide sulfates. These are disaccharides carrying one or more sulfate group on a sugar unit.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassDisaccharides
Direct ParentDisaccharide sulfates
Alternative Parents
Substituents
  • Disaccharide sulfate
  • O-glycosyl compound
  • Glycosyl compound
  • Alkyl sulfate
  • Oxane
  • Oxolane
  • Organic sulfuric acid or derivatives
  • Oxacycle
  • Organic metal salt
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the short-term treatment (up to 8 weeks) of active duodenal ulcer, as well as maintenance therapy for duodenal ulcer patients at reduced dosage (1 gram twice a day) after healing of acute ulcers. Also used for the short-term treatment of gastric ulcer.
PharmacodynamicsSucralfate is a prescription medication used to treat peptic ulcers. The current clinical uses of sucralfate are limited. It is effective for the healing of duodenal ulcers, but it is not frequently used for this since more effective drugs (e.g. proton pump inhibitors) have been developed. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. Chemically, sucralfate is a complex of the disaccharide sugar, sucrose, combined with sulfate and aluminum. In acidic solutions (e.g. gastric acid) it forms a thick paste that has a strong negative charge.
Mechanism of actionAlthough sucralfate's mechanism is not entirely understood, there are several factors that most likely contribute to its action. Sucralfate, with its strong negative charge, binds to exposed positively-charged proteins at the base of ulcers. In this way, it coats the ulcer and forms a physical barrier that protects the ulcer surface from further injury by acid and pepsin. It directly inhibits pepsin (an enzyme that breaks apart proteins) in the presence of stomach acid and binds bile salts coming from the liver via the bile thus protecting the stomach lining from injury caused by the bile acids. Sucralfate may increase prostaglandin production. Prostaglandins are known to protect the lining of the stomach and may also bind epithelial growth factor and fibroblast growth factor, both of which enhance the growth and repair mechanism of the stomach lining.
Related Articles
AbsorptionMinimally absorbed from the gastrointestinal tract (up to 5% of the disaccharide component and less than 0.02% of aluminum).
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationThe small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.
Half lifeNot known.
ClearanceNot Available
ToxicityAcute oral toxicity (LD50) in mice is >8000 mg/kg. There is limited experience in humans with overdosage of sucralfate. Sucralfate is only minimally absorbed from the gastrointestinal tract and thus risks associated with acute overdosage should be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7959
Blood Brain Barrier+0.8803
Caco-2 permeable-0.6433
P-glycoprotein substrateNon-substrate0.8087
P-glycoprotein inhibitor INon-inhibitor0.5656
P-glycoprotein inhibitor IINon-inhibitor0.986
Renal organic cation transporterNon-inhibitor0.8471
CYP450 2C9 substrateNon-substrate0.8611
CYP450 2D6 substrateNon-substrate0.8256
CYP450 3A4 substrateNon-substrate0.6233
CYP450 1A2 substrateNon-inhibitor0.772
CYP450 2C9 inhibitorNon-inhibitor0.8211
CYP450 2D6 inhibitorNon-inhibitor0.8865
CYP450 2C19 inhibitorNon-inhibitor0.7869
CYP450 3A4 inhibitorNon-inhibitor0.9828
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.5805
CarcinogenicityNon-carcinogens0.5356
BiodegradationNot ready biodegradable0.8432
Rat acute toxicity2.4219 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7937
hERG inhibition (predictor II)Non-inhibitor0.8793
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Axcan pharma us inc
  • Nostrum laboratories inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral1000 mg
Suspensionoral1 g/10mL
Tabletoral1 g/1
Suspensionoral100 mg
Suspensionoral1 g
Tabletoral1 g
Prices
Unit descriptionCostUnit
Sucralfate 1 gm/10ml Suspension 10ml Cup13.99USD cup
Carafate 1 gm tablet1.45USD tablet
Sucralfate 1 gm tablet0.72USD tablet
Sucralfate powder0.6USD g
Sulcrate 1 g Tablet0.59USD tablet
Apo-Sucralfate 1 g Tablet0.31USD tablet
Novo-Sucralate 1 g Tablet0.31USD tablet
Nu-Sucralfate 1 g Tablet0.31USD tablet
Pms-Sucralfate 1 g Tablet0.31USD tablet
Carafate 1 gm/10ml Suspension0.24USD ml
Sulcrate Suspension Plus 200 mg/ml Suspension0.11USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble in cold waterNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.714 mg/mLALOGPS
logP0.98ALOGPS
logP-5.6ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count35ChemAxon
Hydrogen Donor Count16ChemAxon
Polar Surface Area772.17 Å2ChemAxon
Rotatable Bond Count36ChemAxon
Refractivity175.09 m3·mol-1ChemAxon
Polarizability105.22 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Nick V. Lazaridis, Moo K. Park, Yousry Sayed, “Method for preparing high potency sucralfate.” U.S. Patent US4990610, issued March, 1973.

US4990610
General References
  1. Rees WD: Mechanisms of gastroduodenal protection by sucralfate. Am J Med. 1991 Aug 8;91(2A):58S-63S. [PubMed:1715673 ]
External Links
ATC CodesA02BX02
AHFS Codes
  • 56:28.32
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolSucralfate may decrease the anticoagulant activities of Acenocoumarol.
AlfacalcidolThe serum concentration of Sucralfate can be increased when it is combined with Alfacalcidol.
CalcitriolThe serum concentration of Sucralfate can be increased when it is combined with Calcitriol.
CholecalciferolThe serum concentration of Sucralfate can be increased when it is combined with Cholecalciferol.
Cholic AcidSucralfate can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Sucralfate.
DemeclocyclineSucralfate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DicoumarolSucralfate may decrease the anticoagulant activities of Dicoumarol.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Sucralfate.
DihydrotachysterolThe serum concentration of Sucralfate can be increased when it is combined with Dihydrotachysterol.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Sucralfate.
DoxercalciferolThe serum concentration of Sucralfate can be increased when it is combined with Doxercalciferol.
DoxycyclineSucralfate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Sucralfate.
ErgocalciferolThe serum concentration of Sucralfate can be increased when it is combined with Ergocalciferol.
FurosemideThe serum concentration of Furosemide can be decreased when it is combined with Sucralfate.
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Sucralfate.
ItraconazoleSucralfate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
KetoconazoleSucralfate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Sucralfate.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Sucralfate.
MinocyclineSucralfate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
MoxifloxacinThe serum concentration of Moxifloxacin can be decreased when it is combined with Sucralfate.
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Sucralfate.
OfloxacinThe serum concentration of Ofloxacin can be decreased when it is combined with Sucralfate.
OxytetracyclineSucralfate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
ParicalcitolThe serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.
PosaconazoleSucralfate can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Sucralfate.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Sucralfate.
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Sucralfate.
TetracyclineSucralfate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
VoriconazoleSucralfate can cause a decrease in the absorption of Voriconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
WarfarinSucralfate may decrease the anticoagulant activities of Warfarin.
Food Interactions
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

Targets

1. Pepsin
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
inhibitor
References
  1. Jensen SL, Funch Jensen P: Role of sucralfate in peptic disease. Dig Dis. 1992;10(3):153-61. [PubMed:1611711 ]
  2. Hollander D, Tarnawski A: The protective and therapeutic mechanisms of sucralfate. Scand J Gastroenterol Suppl. 1990;173:1-5. [PubMed:2190304 ]
  3. Peterson WL: Pathogenesis and therapy of peptic ulcer disease. J Clin Gastroenterol. 1990;12 Suppl 2:S1-6. [PubMed:1978840 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function:
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name:
FGF2
Uniprot ID:
P09038
Molecular Weight:
30769.715 Da
References
  1. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124 ]
  2. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218 ]
  3. Szabo S, Kusstatscher S, Sakoulas G, Sandor Z, Vincze A, Jadus M: Growth factors: new 'endogenous drugs' for ulcer healing. Scand J Gastroenterol Suppl. 1995;210:15-8. [PubMed:8578198 ]
  4. Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [PubMed:1970337 ]
  5. Korman MG, Bolin TD, Szabo S, Hunt RH, Marks IN, Glise H: Sucralfate: the Bangkok review. J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):412-5. [PubMed:7948825 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Transmembrane receptor protein tyrosine kinase activator activity
Specific Function:
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMe...
Gene Name:
EGF
Uniprot ID:
P01133
Molecular Weight:
133993.12 Da
References
  1. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ: Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9-14. [PubMed:8578218 ]
  2. Szabo S: The mode of action of sucralfate: the 1 x 1 x 1 mechanism of action. Scand J Gastroenterol Suppl. 1991;185:7-12. [PubMed:1957124 ]
  3. Konturek SJ: Role of growth factors in gastroduodenal protection and healing of peptic ulcers. Gastroenterol Clin North Am. 1990 Mar;19(1):41-65. [PubMed:1970337 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Structural molecule activity
Specific Function:
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelializati...
Gene Name:
FGA
Uniprot ID:
P02671
Molecular Weight:
94972.455 Da
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Structural molecule activity
Specific Function:
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelializat...
Gene Name:
FGB
Uniprot ID:
P02675
Molecular Weight:
55927.9 Da
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Structural molecule activity
Specific Function:
Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregat...
Gene Name:
FGG
Uniprot ID:
P02679
Molecular Weight:
51511.29 Da
References
  1. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Terao N, Yoshida N, Nagashima R: Sucralfate, a basic aluminum salt of sucrose sulfate. III. Inhibition of peptic hydrolysis of fibrinogen by sucrose sulfate. Arzneimittelforschung. 1980;30(1):76-8. [PubMed:6892775 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on November 04, 2013 16:36